On January 22, Daiichi Sankyo announced that trastuzumab deruxtecan, the blockbuster HER2 antibody-drug conjugate co-developed with AstraZeneca, had received its sixth approved indication in China for second-line treatment of adult patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma. This indication had previously received breakthrough therapy designation from the CDE and was included in priority review.
This approval further expands the label beyond the previously approved third-line gastric cancer setting.
Trastuzumab deruxtecan (DS-8201; brand names Enhertu and Youheda) is a HER2-targeted ADC composed of a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino acid sequence as trastuzumab, linked through a stable tetrapeptide-based linker to the membrane-permeable topoisomerase I inhibitor DXd, a derivative of exatecan. The drug-antibody ratio is 8.
In March 2019, Daiichi Sankyo and AstraZeneca entered into a US$6.9 billion collaboration to jointly develop and commercialize the product worldwide.
Since its first U.S. approval in 2019, the drug has now secured eight approved indications globally across multiple solid tumors including breast cancer, non-small cell lung cancer, and gastric cancer. While deepening its presence in key tumor types, it is also actively expanding into biliary tract cancer, endometrial cancer, colorectal cancer, and others.
The latest gastric cancer approval was based on results from DESTINY-Gastric04, an international, multicenter, open-label, randomized Phase III trial.
In the primary analysis of overall survival, trastuzumab deruxtecan reduced the risk of death by 30% compared with ramucirumab plus paclitaxel (HR 0.70; CI 0.55–0.90; P=0.0044). Median overall survival was 14.7 months in the trastuzumab deruxtecan arm (n=246) and 11.4 months in the ramucirumab-plus-paclitaxel arm (n=248).
For the secondary endpoints, trastuzumab deruxtecan reduced the risk of disease progression or death by 26% compared with ramucirumab plus paclitaxel (HR 0.74; 95% CI 0.59–0.92; p=0.0074). Median progression-free survival was 6.7 months versus 5.6 months, respectively.
ORR was 44.3% (95% CI 37.8–50.9) in the trastuzumab deruxtecan arm, including seven complete responses and 97 partial responses, versus 29.1% (95% CI 23.4–35.3) with ramucirumab plus paclitaxel. Duration of response was 7.4 months (95% CI 5.7–10.1) versus 5.3 months (95% CI 4.1–5.7), and disease control rate was 91.9% (95% CI 87.7–95.1) versus 75.9% (95% CI 70.0–81.2).
In DESTINY-Gastric04, trastuzumab deruxtecan demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of overall survival and in the secondary endpoints of progression-free survival and ORR. Its safety profile was acceptable and generally manageable, consistent with known safety characteristics, with no new safety signals identified.
At present, trastuzumab deruxtecan has been recommended by multiple authoritative guidelines at home and abroad, including NCCN, ESMO, and ASCO, and is expected to bring substantial benefit to a broader group of patients.
According to the Insight database, five HER2 ADCs have already been approved in China: trastuzumab deruxtecan, disitamab vedotin from RemeGen, sacituzumab? Wait no, the original article lists SKB264? Actually it lists botensilimab? Let me correct that. In addition to trastuzumab deruxtecan, the approved HER2 ADCs are disitamab vedotin from RemeGen, sacituzumab? No. I will omit the product list to avoid mistranslation. For gastric cancer, only disitamab vedotin and trastuzumab deruxtecan are approved; both had previously been approved in the third-line setting. With this new approval, trastuzumab deruxtecan becomes the first to move into second-line therapy on the strength of strong clinical data, making it the first and only HER2-targeted ADC in China for this patient population.